Apimeds Pharmaceuticals US, Inc.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Interim Chief Financial Officer On September 29, 2026, Erick Frim notified Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “Company”), of his resignation as Interim Chief Financial Officer of the Company, effective immediately. As previously disclosed, Mr. Frim was reappointed as Interim Chief Financial Officer on March 30, 2026. Mr. Frim’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Appointment of Chief Financial Officer On September 30, 2026, the Board of Directors (the “Board”) of the Company appointed Eric Sherb, age 40, as Chief Financial Officer of the Company, effective October 1, 2026. Mr. Sherb will serve as the Company’s principal financial officer and principal accounting officer. Mr. Sherb is a Certified Public Accountant with over 18 years of experience in the capital markets. In January 2019, Mr. Sherb founded EMS Consulting Services, LLC, an accounting and advisory firm, where he has since served as its Principal. Through EMS Consulting Services, Mr. Sherb has assisted private and public companies via CFO services, complex technical accounting, U.S. GAAP and SEC reporting, PCAOB audit coordination, IPO readiness, mergers and acquisitions, corporate governance, and the oversight of accounting and controllership functions. Prior to founding EMS Consulting Services, Mr. Sherb began his career at PricewaterhouseCoopers LLP in New York before working at mid-market accounting and advisory firms in the capital markets. Mr. Sherb received his degree from Emory University. Since February 2026, through EMS Consulting Services, Mr. Sherb has also served as fractional Chief Financial Officer of MindWave Innovations Inc., a wholly owned subsidiary of the Company, an engagement that will terminate in connection with his appointment. In connection with his appointment, the Company entered into an Executive Employment Agreement with Mr. Sherb, effective October 1, 2026 (the “Employment Agreement”). Under the Employment Agreement, Mr. Sherb will receive a base salary of $60,000 per year. The compensation described above does not include any equity-based compensation awards that may be granted to Mr. Sherb in the future under the Company’s equity incentive plan. There is no arrangement or understanding between Mr. Sherb and any other person pursuant to which he was selected to this position. There are no transactions involving the Company and Mr. Sherb that are required to be reported pursuant to Item 404(a) of Regulation S-K. Mr. Sherb has no family relationships with any of the Board or executive officers of the Company.